| Species |
Human |
| Protein Construction |
MIP-1α/CCL3 (Ser24-Ala92)
Accession # P10147 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 1 EU/μg of protein by LAL method |
| Expression System |
E. coli |
| Apparent Molecular Weight |
~12 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized from a 0.2 μm filtered solution in 20 mM PB, 150 mM NaCl, pH 7.4. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Upon reconstitution, the product should be stable for up to 1 week at 4-7°C and up to 3 months at -20 °C or below. Avoid repeated freeze-thaw cycles. |
| Target Background |
Human Chemokine (C-C Motif) Ligand 3 (CCL3) is a small cytokine belonging to the CC chemokine family. CCL3 is primarily expressed in T cells, B cells, and monocytes after antigen or mitogen stimulation. CCL3 exhibits chemoattractive and adhesive effects on lymphocytes. CCL3 exerts multiple effects on hematopoietic precursor cells and inhibits the proliferation of hematopoietic stem cells in vitro as well as in vivo. CCR1 and CCR5 have been identified as functional receptors for CCL3. |
| Synonyms |
C-C Motif Chemokine 3; G0/G1 Switch Regulatory Protein 19-1; Macrophage Inflammatory Protein 1-Alpha; MIP-1-Alpha; PAT 464.1; SIS-Beta; Small-Inducible Cytokine A3; Tonsillar Lymphocyte LD78 Alpha Protein; CCL3; G0S19-1; MIP1A; SCYA3 |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
